[Myeloproliferative neoplasms and vascular diseases]

Area of Science:

• Hematology
• Cardiovascular Medicine
• Oncology

Background:

• Vascular diseases are common in myeloproliferative neoplasms (MPNs) with driver mutations like JAK2V617F.
• Clonal hematopoiesis with JAK2V617F (JAK2V617F-CH) is increasingly associated with vascular complications, even before MPN diagnosis.
• These complications include thrombosis, coronary artery disease, aortic aneurysm, and pulmonary hypertension.

Purpose of the Study:

• To explore the link between MPN driver mutations and vascular diseases.
• To understand the mechanisms by which JAK2V617F-CH contributes to vascular pathologies.
• To identify potential therapeutic targets within the JAK-STAT pathway for vascular disease prevention and treatment in MPN patients.

Main Methods:

• Review of existing literature on MPNs, JAK2V617F-CH, and associated vascular diseases.
• Analysis of murine studies investigating the role of mutated hematopoietic cells in vascular remodeling and thrombosis.
• Examination of downstream signaling molecules in the JAK-STAT pathway activated by MPN driver mutations.

Main Results:

• MPN driver mutations, particularly JAK2V617F, are implicated in arterial/venous thrombosis, atherosclerotic coronary artery disease, aortic aneurysm, and pulmonary hypertension.
• Murine models demonstrate that activated hematopoietic cells promote thrombosis and vascular remodeling in conditions like deep vein stenosis, atherosclerosis, and pulmonary hypertension.
• JAK-STAT activation in neutrophils and macrophages by MPN driver mutations leads to the release of inflammatory cytokines.

Conclusions:

• Hematopoietic cells harboring MPN driver mutations play a significant role in the pathogenesis of vascular diseases.
• The JAK-STAT signaling pathway and its downstream inflammatory cytokines are potential therapeutic targets for managing vascular complications in MPNs and JAK2V617F-CH.
• Further research into these mechanisms could lead to novel preventative and treatment strategies for vascular diseases in affected individuals.